Neurocrine Biosciences (NBIX) Receivables (2010 - 2026)

Neurocrine Biosciences' Receivables history runs 17 years deep, the most recent figure standing at $768.1 million for Q1 2026.

• Quarterly Receivables rose 48.86% year-over-year to $768.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $768.1 million (up 48.86% YoY) and the FY2025 annual result came in at $707.3 million, up 43.32% from the prior year.
• Receivables was $768.1 million for Q1 2026 at Neurocrine Biosciences, up from $707.3 million in the prior quarter.
• Across five years, Receivables topped out at $768.1 million in Q1 2026 and bottomed at $266.5 million in Q1 2022.
• A 5-year average of $476.2 million and a median of $463.3 million in 2024 frame the typical range for Receivables.
• Annual changes were most pronounced in 2022 — Receivables soared 88.97% — and 2024, when it advanced 9.54%.
• Neurocrine Biosciences' Receivables stood at $354.7 million in 2022, then advanced by 27.01% to $450.5 million in 2023, then grew by 9.54% to $493.5 million in 2024, then soared by 43.32% to $707.3 million in 2025, then advanced by 8.6% to $768.1 million in 2026.
• Business Quant data shows NBIX's Receivables at $768.1 million in Q1 2026, $707.3 million in Q4 2025, and $728.0 million in Q3 2025.